Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors
Infection and Drug Resistance · 2024-09 · Volume 17 · 3793-3804
DOI: 10.2147/idr.s473200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2024-09. Verfasst von Ying-Chao Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, People's Republic of China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
To assess the efficacy and safety of colistin sulfate in treating infections caused by carbapenem-resistant organisms (CRO) and to analyze potential factors impacting its effectiveness.
Methods
In this retrospective study, medical records of CRO-infected patients from June 2020 to June 2023 were analyzed, divided into effective and ineffective treatment groups, and compared for clinical outcomes and adverse reactions. Multifactorial logistic regression and ROC curve analysis were used to identify influencing factors.
Results
The study included 226 patients, with 124 in the effective treatment group and 102 in the ineffective group. A total of 293 CRO strains were cultured. The clinical efficacy rate of colistin sulfate was 54.87%, the microbiological efficacy rate 46.46%, and the hospital mortality rate 20.80%, with nephrotoxicity observed in 11.50% of patients. Multifactorial analysis identified APACHE II scores and vasoactive drug use as independent predictors of ineffective treatment, while treatment duration and albumin levels predicted effective treatment. ROC analysis indicated that albumin levels >34 g/L, APACHE II scores 10 days correlated with better clinical efficacy.
Conclusion
Colistin sulfate is both safe and effective in clinical settings. Factors such as treatment duration, albumin levels, APACHE II scores, and vasoactive drug use independently affect its clinical efficacy, providing valuable guidance for its informed clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, People's Republic of China.
- College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei Province, 050000, People's Republic of China.
- Department of Cardiac Surgery, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050000, People's Republic of China.
Zitieren
APA
Ma, Y. C., Sun, Y. Q., Wu, X., Wang, Y. J., Yang, X. L., & Gu, J. J. (2024). Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors. Infection and Drug Resistance, Volume 17, 3793-3804. https://doi.org/10.2147/idr.s473200
Vancouver
Ma YC, Sun YQ, Wu X, Wang YJ, Yang XL, Gu JJ. Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors. Infection and Drug Resistance. 2024;Volume 17:3793-3804. doi:10.2147/idr.s473200
BibTeX
@article{Ma2024,
author = {Ma, Ying-Chao and Sun, Ya-Qing and Wu, Xia and Wang, Yong-Jing and Yang, Xiu-Ling and Gu, Jian-Jun},
title = {Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors},
journal = {Infection and Drug Resistance},
year = {2024},
volume = {Volume 17},
pages = {3793--3804},
doi = {10.2147/idr.s473200}
}
EUVIMED